These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

477 related items for PubMed ID: 24118469

  • 1. Validation of EUCAST zone diameter breakpoints against reference broth microdilution.
    Bengtsson S, Bjelkenbrant C, Kahlmeter G.
    Clin Microbiol Infect; 2014 Jun; 20(6):O353-60. PubMed ID: 24118469
    [Abstract] [Full Text] [Related]

  • 2. Assessment of the Phoenix™ automated system and EUCAST breakpoints for antimicrobial susceptibility testing against isolates expressing clinically relevant resistance mechanisms.
    Giani T, Morosini MI, D'Andrea MM, García-Castillo M, Rossolini GM, Cantón R.
    Clin Microbiol Infect; 2012 Nov; 18(11):E452-8. PubMed ID: 22909279
    [Abstract] [Full Text] [Related]

  • 3. Antimicrobial susceptibility testing of Kingella kingae with broth microdilution and disk diffusion using EUCAST recommended media.
    Matuschek E, Åhman J, Kahlmeter G, Yagupsky P.
    Clin Microbiol Infect; 2018 Apr; 24(4):396-401. PubMed ID: 28760709
    [Abstract] [Full Text] [Related]

  • 4. Development of the EUCAST disk diffusion antimicrobial susceptibility testing method and its implementation in routine microbiology laboratories.
    Matuschek E, Brown DF, Kahlmeter G.
    Clin Microbiol Infect; 2014 Apr; 20(4):O255-66. PubMed ID: 24131428
    [Abstract] [Full Text] [Related]

  • 5. BSAC standardized disc susceptibility testing method (version 7).
    Andrews JM, BSAC Working Party on Susceptibility Testing.
    J Antimicrob Chemother; 2008 Aug; 62(2):256-78. PubMed ID: 18474513
    [Abstract] [Full Text] [Related]

  • 6. Antimicrobial susceptibility of gram-negative and gram-positive bacteria collected from countries in Eastern Europe: results from the Tigecycline Evaluation and Surveillance Trial (T.E.S.T.) 2004-2010.
    Balode A, Punda-Polić V, Dowzicky MJ.
    Int J Antimicrob Agents; 2013 Jun; 41(6):527-35. PubMed ID: 23590898
    [Abstract] [Full Text] [Related]

  • 7. BSAC standardized disc susceptibility testing method (version 10).
    Andrews JM, Howe RA, BSAC Working Party on Susceptibility Testing.
    J Antimicrob Chemother; 2011 Dec; 66(12):2726-57. PubMed ID: 21921076
    [Abstract] [Full Text] [Related]

  • 8. In vitro antibacterial activity of doripenem against clinical isolates from French teaching hospitals: proposition of zone diameter breakpoints.
    Lascols C, Legrand P, Mérens A, Leclercq R, Armand-Lefevre L, Drugeon HB, Kitzis MD, Muller-Serieys C, Reverdy ME, Roussel-Delvallez M, Moubareck C, Lemire A, Miara A, Gjoklaj M, Soussy CJ.
    Eur J Clin Microbiol Infect Dis; 2011 Apr; 30(4):475-82. PubMed ID: 21088861
    [Abstract] [Full Text] [Related]

  • 9. Development of a national EUCAST challenge panel for antimicrobial susceptibility testing.
    Desmet S, Verhaegen J, Glupzcynski Y, Van Eldere J, Melin P, Goossens H, Piérard D, Declercq P, Lagrou K, Boel A, Cartuyvels R, Denis O, Vandewal W, Saegeman V.
    Clin Microbiol Infect; 2016 Aug; 22(8):704-10. PubMed ID: 27234934
    [Abstract] [Full Text] [Related]

  • 10. Antimicrobial susceptibility testing of pathogens isolated from blood culture: a performance comparison of Accelerate Pheno™ and VITEK® 2 systems with the broth microdilution method.
    De Angelis G, Posteraro B, Menchinelli G, Liotti FM, Spanu T, Sanguinetti M.
    J Antimicrob Chemother; 2019 Jan 01; 74(Suppl 1):i24-i31. PubMed ID: 30690539
    [Abstract] [Full Text] [Related]

  • 11. In vitro antibacterial activity of ceftobiprole against clinical isolates from French teaching hospitals: proposition of zone diameter breakpoints.
    Lascols C, Legrand P, Mérens A, Leclercq R, Muller-Serieys C, Drugeon HB, Kitzis MD, Reverdy ME, Roussel-Delvallez M, Moubareck C, Brémont S, Miara A, Gjoklaj M, Soussy CJ.
    Int J Antimicrob Agents; 2011 Mar 01; 37(3):235-9. PubMed ID: 21295447
    [Abstract] [Full Text] [Related]

  • 12. Evaluation of PPI-0903M (T91825), a novel cephalosporin: bactericidal activity, effects of modifying in vitro testing parameters and optimization of disc diffusion tests.
    Jones RN, Fritsche TR, Ge Y, Kaniga K, Sader HS.
    J Antimicrob Chemother; 2005 Dec 01; 56(6):1047-52. PubMed ID: 16239290
    [Abstract] [Full Text] [Related]

  • 13. Antimicrobial susceptibility testing breakpoints and methods from BSAC to EUCAST.
    Brown DF, Wootton M, Howe RA.
    J Antimicrob Chemother; 2016 Jan 01; 71(1):3-5. PubMed ID: 26377864
    [Abstract] [Full Text] [Related]

  • 14. Contemporary tetracycline susceptibility testing: doxycycline MIC methods and interpretive criteria (CLSI and EUCAST) performance when testing Gram-positive pathogens.
    Jones RN, Stilwell MG, Wilson ML, Mendes RE.
    Diagn Microbiol Infect Dis; 2013 May 01; 76(1):69-72. PubMed ID: 23490012
    [Abstract] [Full Text] [Related]

  • 15. Comparison of antimicrobial pharmacokinetic/pharmacodynamic breakpoints with EUCAST and CLSI clinical breakpoints for Gram-positive bacteria.
    Asín E, Isla A, Canut A, Rodríguez Gascón A.
    Int J Antimicrob Agents; 2012 Oct 01; 40(4):313-22. PubMed ID: 22921422
    [Abstract] [Full Text] [Related]

  • 16. Telavancin activity tested against Gram-positive clinical isolates from European, Russian and Israeli hospitals (2011-2013) using a revised broth microdilution testing method: redefining the baseline activity of telavancin.
    Mendes RE, Flamm RK, Farrell DJ, Sader HS, Jones RN.
    J Chemother; 2016 Apr 01; 28(2):83-8. PubMed ID: 26058844
    [Abstract] [Full Text] [Related]

  • 17. Comparison of disc diffusion, Etest and broth microdilution for testing susceptibility of carbapenem-resistant P. aeruginosa to polymyxins.
    van der Heijden IM, Levin AS, De Pedri EH, Fung L, Rossi F, Duboc G, Barone AA, Costa SF.
    Ann Clin Microbiol Antimicrob; 2007 Aug 15; 6():8. PubMed ID: 17697363
    [Abstract] [Full Text] [Related]

  • 18. Contemporary potencies of minocycline and tetracycline HCL tested against Gram-positive pathogens: SENTRY Program results using CLSI and EUCAST breakpoint criteria.
    Jones RN, Wilson ML, Weinstein MP, Stilwell MG, Mendes RE.
    Diagn Microbiol Infect Dis; 2013 Apr 15; 75(4):402-5. PubMed ID: 23514756
    [Abstract] [Full Text] [Related]

  • 19. Vibrio species: development of EUCAST susceptibility testing methods and MIC and zone diameter distributions on which to determine clinical breakpoints.
    Karatuna O, Matuschek E, Åhman J, Caidi H, Kahlmeter G.
    J Antimicrob Chemother; 2024 Feb 01; 79(2):375-382. PubMed ID: 38158720
    [Abstract] [Full Text] [Related]

  • 20. Consequences of switching from a fixed 2 : 1 ratio of amoxicillin/clavulanate (CLSI) to a fixed concentration of clavulanate (EUCAST) for susceptibility testing of Escherichia coli.
    Leverstein-van Hall MA, Waar K, Muilwijk J, Cohen Stuart J, ISIS-AR Study Group.
    J Antimicrob Chemother; 2013 Nov 01; 68(11):2636-40. PubMed ID: 23766488
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.